Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AL-4943A in Allergic Conjunctivitis
NCT01037179Phase 3Completed
- Sponsor
- Alcon Inc.
- Start
- Feb 2010
- Primary completion
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of olopatadine in allergic conjunctivitis (AC), sponsored by Alcon Inc. Primary endpoints: Mean Itching Score by Visit and Mean Total Hyperemia Score by Visit. Started Feb 2010; status: completed.
02
Drugs
olopatadine
03
Conditions
allergic conjunctivitis (AC)
Beyond the preview
Go deeper on NCT01037179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01037179.